Anditixafortide
Based on 1 Customer Validation
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative. Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.99%
- No. CAS: 1821136-83-7
- Fòrmula: C60H79IN14O14
- Peso molecular:1347.26
-
Almacenamiento:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas Radionuclide-Drug Conjugates (RDCs)
More
Actividad biológica
|
RDC Peptide |
Chemical Information
-
No. CAS 1821136-83-7
-
Appearance Solid
-
Peso molecular 1347.26
-
Fòrmula C60H79IN14O14
-
Color White to off-white
-
Sequence
cyclo(Nal-Gly-(3-I-d-Tyr)-(N-Me-Orn(AMBA-DOTA)))
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvente y solubilidad
DMSO : 50 mg/mL (37.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Nicolas Lepareur, et al. Clinical Advances and Perspectives in Targeted Radionuclide Therapy. Pharmaceutics. 223, 15, 6. [Content Brief]
[2]. Ken Herrmann, et al. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. J Nucl Med. 2016, 57, 2. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.7422 mL | 3.7112 mL | 7.4225 mL | 18.5562 mL |
| 5 mM | 0.1484 mL | 0.7422 mL | 1.4845 mL | 3.7112 mL | |
| 10 mM | 0.0742 mL | 0.3711 mL | 0.7422 mL | 1.8556 mL | |
| 15 mM | 0.0495 mL | 0.2474 mL | 0.4948 mL | 1.2371 mL | |
| 20 mM | 0.0371 mL | 0.1856 mL | 0.3711 mL | 0.9278 mL | |
| 25 mM | 0.0297 mL | 0.1484 mL | 0.2969 mL | 0.7422 mL | |
| 30 mM | 0.0247 mL | 0.1237 mL | 0.2474 mL | 0.6185 mL |
Anditixafortide Related Classifications
HY-P2218 Related Classifications
Powered by Bioz